Best Earnings Power Value Biological Products, (No Diagnostic Substances) Stocks 2026

Top Biological Products, (No Diagnostic Substances) stocks by Earnings Power Value (EPV) upside in 2026. Greenwald-framework valuation updated daily from SEC filings.

58 stocks analyzed Updated 2026-05-29
# Ticker Company QOC Price EPV Upside
1 ATRA Atara Biotherapeutics, Inc. 4.8 $10.51 +496.1%
2 CHRS Coherus Oncology, Inc. 6.8 $1.59 +450.0%
3 VIVS VivoSim Labs, Inc. 4.5 $1.31 +114.7%
4 MRNA Moderna, Inc. 7.1 $47.19 +80.9%
5 SABS SAB Biotherapeutics, Inc. 5.0 $3.60 +77.9%
6 BDTX Black Diamond Therapeutics, Inc 6.8 $2.22 +64.1%
7 IMA ImageneBio, Inc. 5.8 $5.88 +54.6%
8 PLX Protalix BioTherapeutics, Inc. 7.6 $2.11 +51.4%
9 CGEN Compugen Ltd. 9.0 $2.63 +25.6%
10 IMCR Immunocore Holdings plc 8.2 $28.89 +1.9%
11 X••• X4 ••••• •.• $•••.•• ••.•%
12 E••• Elutia, ••••• •.• $•••.•• ••.•%
13 C••• Creative ••••• •.• $•••.•• ••.•%
14 P••• Pelthos ••••• •.• $•••.•• ••.•%
15 I••• Immunovant, ••••• •.• $•••.•• ••.•%
16 Q••• Qiagen ••••• •.• $•••.•• ••.•%
17 E••• Exelixis, ••••• •.• $•••.•• ••.•%
18 V••• Vir ••••• •.• $•••.•• ••.•%
19 C••• CRISPR ••••• •.• $•••.•• ••.•%
20 B••• Beam ••••• •.• $•••.•• ••.•%
🔒

Unlock the Full Best Earnings Power Value Biological Products, (No Diagnostic Substances) Stocks 2026 List

Screen all 58 Biological Products, (No Diagnostic Substances) stocks with 13 institutional-grade valuation models. Updated daily from SEC EDGAR filings.

Access Full Screening — From $27/mo →

How CirclFi Ranks Biological Products, (No Diagnostic Substances) Stocks

CirclFi analyzes 58 Biological Products, (No Diagnostic Substances) stocks daily using 13 independent institutional-grade valuation models. Each model processes SEC EDGAR 10-K and 10-Q financial filings (700+ XBRL tags), FRED macroeconomic data, and GDELT news sentiment.

The best earnings power value biological products, (no diagnostic substances) stocks 2026 ranking uses epv upside as the primary sort criterion. Models span intrinsic valuation (Bayesian DCF with 10,000 Monte Carlo simulations, EPV), scenario analysis (First Chicago), regime-switching (Markov DDM), and machine learning (ML-RIV, FTNN Topology).